Asuragen, microRNA Rx Subsidiary Awarded NIH Grants to Support Rx, Dx-Development

The grant issued to Asuragen will help the company identify miRNA biomarkers for colon cancer recurrence, while Mirna Therapeutics' grant will fund its efforts to develop prostate cancer drugs based on the small, non-coding RNAs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.